Dare Bioscience, Inc.

0001401914 FALSE 12/31 0001401914 2026-04-13 2026-04-13 0001401914 2026-01-01 2026-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2026 DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-36395 20-4139823 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3655 Nobel Drive , Suite 260 San Diego , CA 92122 (Address of Principal Executive Offices and Zip Code) Registrant’s telephone number, including area code: ( 858 ) 926-7655 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock DARE Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 10, 2026, the board of directors of Daré Bioscience, Inc. (the “Company”), approved an amendment to the Third Amended and Restated By-Laws of the Company, effective immediately, to reduce the quorum requirement for all stockholder meetings of the Company from the holders of a majority in voting power of the shares of the capital stock of the Company issued and outstanding and entitled to vote at the meeting to the holders of at least one-third of the voting power of the shares of the capital stock of the Company issued and outstanding and entitled to vote at the meeting. The foregoing description of the amendment is qualified in its entirety by reference to the full text of the amendment, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 3.1 Amendment to Third Amended and Restated By-Laws of Daré Bioscience, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DARÉ BIOSCIENCE, INC. Dated: September 11, 2026 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer